Procter & Gamble Jumps 6% as Earnings Beat Draws Defensive Buyers; Johnson & Johnson Rises 3%, Coca-Cola Ticks Up

Defensive consumer and healthcare stocks are drawing fresh money. As large-caps generally fall, Procter & Gamble‘s (NYSE:PG | PG Price Prediction) quarterly beat is catching the interest of today’s buyers. Procter & Gamble stock is up 6% to $166.19 in morning trading, a jump suggesting that the company’s price increases are holding up with consumers. That advance puts Procter & Gamble shares on course for their biggest gain since 2020 and pushes their climb year to date (YTD) to 19%.

The Invesco S&P 500 Low Volatility ETF (NYSEARCA:SPLV) is up 1%, reflecting strength in the calmest corner of the large-cap market. Across the broader index, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is down 1%. Such a split points to money rotating out of technology and into defensive stocks.

Other defensive gainers include Johnson & Johnson (NYSE:JNJ), up 3% to $264.89, and Coca-Cola (NYSE:KO), up 2% to $94.56. So, what’s happening with Procter & Gamble and its peers today?

Procter & Gamble Beat Shows Price Increases Are Sticking

Procter & Gamble’s Q1 FY2027 results delivered core earnings per share (EPS) of $2, exceeding the $1.89 consensus estimate. Net sales at Procter & Gamble reached $23.28 billion, ahead of the $22.82 billion analysts expected. Every one of the company’s business segments beat organic sales growth forecasts, with laundry and home products providing a notable boost.

Procter & Gamble CFO Andre Schulten addressed the U.S. consumer. He stated that the U.S. consumer is “remarkably resilient,” with higher-income households driving the business while lower-income shoppers are more cautious. Management maintained Procter & Gamble’s full-year outlook, including organic sales growth of 1% to 3% and core EPS of $6.89 to $7.11. Keeping that outlook intact tells the market the company’s pricing is landing with shoppers.

Procter & Gamble’s Edge Comes With Cost Pressure

Results at Procter & Gamble carry weaknesses too, and the bear case centers on costs. Its core gross margin fell 150 basis points year over year, and the company expects a $1.4 billion after-tax commodity cost pressure this fiscal year. Executives cautioned on the call, “The strength is real, but it won’t be a straight line.”

Recent fund flows show a preference for quality over momentum within the S&P 500, a background that favors steady compounders like Procter & Gamble. Even after its slide, the SPDR S&P 500 ETF Trust holds a 12% YTD gain, a smaller climb than Procter & Gamble shares now carry. Six straight quarters of exceeding earnings expectations add to the appeal of Procter & Gamble stock.

Procter & Gamble’s Pricing Power Faces Its Next Test

Procter & Gamble must now see whether lower-income shoppers keep accepting its higher prices, since Schulten singled out that group as more cautious. Management expects first-half organic sales growth of 3% with slight acceleration in the second half. Rising input costs complicate that path, with executives noting on the call: “Oil at $113 means more is coming in Q3 and Q4.”

Volume trends at Procter & Gamble offer the clearest read on that question. Organic volume at Procter & Gamble rose 2%. The company credited unit gains with the majority of growth, a sign higher prices haven’t pushed buyers toward cheaper brands. Executives added that “over 70% of our top US customers” are now holding or growing share.

Procter & Gamble’s capital return plan offers a cushion. The plan includes more than $10 billion in dividends and approximately $5 billion in buybacks planned this fiscal year. Traders may prefer to keep their share exposure smaller until Procter & Gamble’s pricing test resolves.

Contact [email protected] for any questions or corrections.